Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;22(3):249-57.
doi: 10.1128/CVI.00718-14. Epub 2014 Dec 24.

Tuberculosis vaccine types and timings

Affiliations
Review

Tuberculosis vaccine types and timings

Ian M Orme. Clin Vaccine Immunol. 2015 Mar.

Abstract

Traditionally, the design of new vaccines directed against Mycobacterium tuberculosis, the most successful bacterial pathogen on the planet, has focused on prophylactic candidates that would be given to individuals while they are still young. It is becoming more apparent, however, that there are several types of vaccine candidates now under development that could be used under various conditions. Thus, in addition to prophylactic vaccines, such as recombinant Mycobacterium bovis BCG or BCG-boosting vaccines, other applications include vaccines that could prevent infection, vaccines that could be given in emergency situations as postexposure vaccines, vaccines that could be used to facilitate chemotherapy, and vaccines that could be used to reduce or prevent relapse and reactivation disease. These approaches are discussed here, including the type of immunity we are trying to specifically target, as well as the limitations of these approaches.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Schematic showing multiple potential applications of certain candidate TB vaccines.

References

    1. World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization, Geneva, Switzerland: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf.
    1. Cohen T, Dye C, Colijn C, Williams B, Murray M. 2009. Mathematical models of the epidemiology and control of drug-resistant TB. Expert Rev Respir Med 3:67–79. doi: 10.1586/17476348.3.1.67. - DOI - PubMed
    1. Dye C. 2009. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 7:81–87. doi: 10.1038/nrmicro2048. - DOI - PubMed
    1. Smith KC, Orme IM, Starke J. 2012. The BCG vaccine, p 789–811. In Plotkin S, Orenstein W, Offit P (ed), Vaccines, 6th ed. W. B. Saunders, Philadelphia, PA.
    1. Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AI, Maeurer M. 2014. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir Med 2:301–320. doi: 10.1016/S2213-2600(14)70033-5. - DOI - PubMed

MeSH terms

LinkOut - more resources